Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
February 5, 2008

Quintessence Retains Althea Technologies to Produce First Lead Candidate

  • Althea Technologies was awarded a contract from Quintessence Biosciences under a manufacturing supply agreement to produce the firm’s first drug candidate.

    QBI-139 is effective in cancer models against a broad range of solid tumors, according to Quintessence. The company plans to file an IND for QBI-139 in the first quarter. Althea will provide protein production, purification, and aseptic filling services to produce the clinical trial materials.

Related content

  • You’re all set! Thank you for subscribing to GEN Highlights.